by Noah Blaine

European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Median progression-free survival and overall response rate doubled among patients receiving EPd compared to pomalidomide and low-dose dexamethasone alone

source https://finance.yahoo.com/news/european-commission-approves-empliciti-elotuzumab-201600166.html?.tsrc=rss

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.